The companies collaborated to manufacture efgartigimod targeting neonatal Fc receptor for sev. autoimmune disease. FUJIFILM will manufacture efgartigimod drug substance at its large-scale biomanufacturing facility in Hillerd, Denmark
FUJIFILM provides expertise and technologies to bring therapy to patients. The collaboration offers the ability for new programs and provides a well-established and strong ecosystem for large-scale production of therapeutic Abs for commercial use
Efgartigimod has been approved in the US & EU for gMG who are AChR Ab & in Japan for gMG who do not have a sufficient response to steroids or non-steroidal immunosuppressive therapies. The therapy is also being studied for other sev. autoimmune diseases
Ref: GlobeNewswire | Image: FUJIFILM
